What is HC Wainwright’s Estimate for RLAY FY2026 Earnings?

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Investment analysts at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Relay Therapeutics in a research report issued on Monday, November 9th. HC Wainwright analyst R. Burns now expects that the company will earn ($1.56) per share for the year, up from their previous estimate of ($1.57). HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q4 2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.40) EPS and FY2027 earnings at ($1.55) EPS.

RLAY has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a report on Friday, October 2nd. JonesTrading boosted their price target on shares of Relay Therapeutics from $20.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Citizens Jmp upped their price objective on Relay Therapeutics from $21.00 to $26.00 and gave the stock a “market outperform” rating in a research report on Monday, August 10th. JPMorgan Chase & Co. increased their price objective on Relay Therapeutics from $28.00 to $31.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Finally, Barclays lifted their target price on Relay Therapeutics from $27.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Relay Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $27.00.

Relay Therapeutics Stock Performance

NASDAQ RLAY opened at $19.96 on Wednesday. The firm has a market cap of $4.41 billion, a price-to-earnings ratio of -13.22 and a beta of 1.74. The firm has a 50 day simple moving average of $18.38 and a 200-day simple moving average of $15.32. Relay Therapeutics has a one year low of $5.95 and a one year high of $21.27.

Relay Therapeutics (NASDAQ:RLAY) last released its earnings results on Wednesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.03.

Institutional Investors Weigh In On Relay Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Eurizon Capital SGR S.p.A. acquired a new position in Relay Therapeutics in the third quarter valued at approximately $33,000. KBC Group NV purchased a new stake in shares of Relay Therapeutics during the 1st quarter worth approximately $34,000. Allworth Financial LP acquired a new position in shares of Relay Therapeutics in the 2nd quarter valued at $34,000. GAMMA Investing LLC boosted its holdings in shares of Relay Therapeutics by 108.3% in the 3rd quarter. GAMMA Investing LLC now owns 2,850 shares of the company’s stock valued at $51,000 after buying an additional 1,482 shares in the last quarter. Finally, Meeder Asset Management Inc. acquired a new position in shares of Relay Therapeutics in the 2nd quarter valued at $62,000. Institutional investors and hedge funds own 96.98% of the company’s stock.

Insider Transactions at Relay Therapeutics

In other news, CEO Sanjiv Patel sold 48,199 shares of the firm’s stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $18.10, for a total value of $872,401.90. Following the sale, the chief executive officer directly owned 471,301 shares in the company, valued at approximately $8,530,548.10. This trade represents a 9.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Peter Rahmer sold 4,508 shares of Relay Therapeutics stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $20.03, for a total transaction of $90,295.24. Following the sale, the insider directly owned 223,657 shares of the company’s stock, valued at approximately $4,479,849.71. This trade represents a 1.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,149,344 shares of company stock valued at $119,185,625 over the last quarter. Insiders own 5.04% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.